Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
NEW YORK, May 11, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, Inc. ("Puma Biotechnology") (NASDAQ:PBYI) between February 29, 2016 and May 4, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Central District of California. To get more information go to:
http://www.zlk.com/pslra-sb/puma-biotechnology-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company did not anticipate that the U.S. Food and Drug Administration (“FDA”) would ultimately approve PB272 (“neratinib”) for the treatment of breast cancer; (ii) as such, Puma Biotechnology had overstated the drug’s approval prospects and/or commercial viability; and (iii) as a result, Puma Biotechnology’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Puma Biotechnology you have until July 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
